TherapeuticsMD saw the highest growth of 0.99% in patent filings and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.99% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of TherapeuticsMD‘s patent filings and grants. Buy the databook here.
TherapeuticsMD has been focused on protecting inventions in Spain(ES) with one publication in Q2 2024
The Spain(ES) Patent Office dominates the patent grants with nearly 100% of grants. The United States(US), and Spain(ES) patent Office are among the top ten patent offices where TherapeuticsMD is filings its patents. Among the top granted patent authorities, TherapeuticsMD has 100% of its grants in Spain(ES).
AbbVie and Roche could be the strongest competitors for TherapeuticsMD
In terms of grant share, TherapeuticsMD stands first among its competitors followed by AbbVie and Roche.
Patents related to rare diseases lead TherapeuticsMD's portfolio
TherapeuticsMD has the highest number of patents in rare diseases. For rare diseases, nearly 100% of patents were filed and 100% of patents were granted in Q2 2024.
Hormone replacement therapy (hrt) related patents lead TherapeuticsMD portfolio followed by menopausal disorders, and mobiles, hand-helds, pdas, smartphones
TherapeuticsMD has highest number of patents in hormone replacement therapy (hrt) followed by menopausal disorders, mobiles, hand-helds, pdas, smartphones.
For comprehensive analysis of TherapeuticsMD's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.